Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia (Q43687599)

25 November 2017

title

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

1 reference

McKenney JM

1

1 reference

25 November 2017

McCormick LS

2

1 reference

25 November 2017

Schaefer EJ

3

1 reference

25 November 2017

Black DM

4

1 reference

25 November 2017

Watkins ML

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

American Journal of Cardiology

25 November 2017

published in

1 reference

25 November 2017

volume

88

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

270-274

1 reference

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Hypertriglyceridemia as a cardiovascular risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Management of primary hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Management of dyslipidemia in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(01)01639-3

1 reference

25 November 2017

1 reference